Lu Fan

Purendan alleviates non-alcoholic fatty liver disease in aged type 2 diabetic rats via regulating mTOR/S6K1/SREBP-1c signaling pathway.

Binan Lu, Zongran Pang, Lu Fan, 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

CLEC4s as Potential Therapeutic Targets in Hepatocellular Carcinoma Microenvironment

M. Fang, Binan Lu, Zongran Pang, 2021, Frontiers in Cell and Developmental Biology.

Genome instability-related LINC02577, LINC01133 and AC107464.2 are lncRNA prognostic markers correlated with immune microenvironment in pancreatic adenocarcinoma

Binan Lu, Zongran Pang, Lu Fan, 2023, BMC Cancer.

The therapeutic mechanism of PuRenDan for the treatment of diabetic nephropathy: Network pharmacology and experimental verification.

Binan Lu, Zongran Pang, Xu He, 2022, Journal of ethnopharmacology.

ACEs family genes: Important molecular links between lung cancer and COVID‐19

Binan Lu, Zongran Pang, Lu Fan, 2021, Clinical and translational medicine.

Comprehensive pan-cancer analysis on CBX3 as a prognostic and immunological biomarker

Peiqiong Chen, Lu Fan, Boyu Sun, 2022, BMC Medical Genomics.